Thought I would share this. It's excellent news in regards to Convalescent Serum/Plasma treatment in regards to COVID-19 and also the promise to provide my much needed treatment. This treatment was done this week at OSU on 2 patients. I am anxiously waiting to hear the results of that study. I am also looking forward to see what these most fabulous companies mentioned in the email below create together. #DONATEPLASMA it's Lifesaving!!!!!!

A message from our CEO to the Hizentra® Immune Globulin Subcutaneous (Human), 20% Liquid Community

Your CSL Behring Team <CSLBehringTeam@email.scigtreatment.com>

4:04 PM (1 hour ago)

to me

Important Safety InformationWARNING: Blood clots can occur with immune globulin products, including Hizentra. If you are at risk for blood clots, Hizentra should be administered at minimum dose and infusion rate practicable and you should be monitored for signs of clotting events. Drink sufficient fluids before infusing. See your doctor for a full explanation of this warning, as well as the Important Safety Information in this email and the prescribing Information, including complete boxed warning and patient product information.

Hizentra(R) | Immune Globulin Subcutaneous (Human), 20% Liquid

A Message From Our CEO

Dear Hizentra Community Member, As the COVID-19 virus situation evolves, we know that the needs of our patients remain the same, and we are committed to our promise of making and delivering life-saving medicines to those who depend on them. We understand that managing a chronic illness during this time can be stressful and you likely have concerns about the safety and availability of your medicines.

I personally want to assure you that our CSL Behring business, including our manufacturing and plasma collection centers, is operating. Despite the current environment, we continue to deliver an uninterrupted supply of our treatments and, as always, are committed to the highest standards of safety and quality for our products, donors and employees.

This global pandemic is a humanitarian crisis that impacts us all. As a leading biotherapeutics company, we understand the responsibilities we have to deliver innovative solutions for high unmet medical needs. That is why I am proud to share with you that CSL Behring was instrumental in forming an unprecedented industry alliance to help develop a therapy for treating people with COVID-19. Together with other plasma-product companies including Biotest, BPL, LFB, Octapharma and Takeda, we will begin work immediately on the development of an anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin medicine. We believe that by bringing together the brightest minds, and leveraging collective resources and expertise, we can achieve more than by working independently. Please refer to our website for more information at cslbehring.com.

On behalf of everyone at CSL Behring, my thoughts are with you and your family, friends, and communities as you manage through these uncertain times, but I am very optimistic about the work we are doing to develop a reliable, scalable and sustainable treatment solution for this devastating pandemic.

Thank you for your trust in CSL Behring. Be safe and be well.

Paul Perreault
CEO and Managing Director
CSL Limited

Biotherapies for Life(R)
CSL Behring

This email has been sent to you because we believe information about Hizentra may be of value to you. If you no longer wish to receive emails from CSL Behring about Hizentra,Hizentra is manufactured by CSL Behring AG and distributed by CSL Behring LLC. Hizentra® is a registered trademark of CSL Behring AG.
Biotherapies for Life® and IgIQ® are registered trademarks of CSL Behring LLC.©2020 CSL Behring LLC 1020 First Avenue, PO Box 61501, King of Prussia, PA 19406-0901 USAwww.CSLBehring.com  www.Hizentra.com